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Abstract
Cancer is the second leading cause of death worldwide. Conventional therapies
cause serious side effects and, at best, merely extend the patient’s lifespan by a few
years. Cancer control may therefore benefit from the potential that resides in
alternative therapies. There is thus an increasing demand to utilize alternative concepts
or approaches to the prevention of cancer. The principal aim of this research is to
screen and identify new synthetic compounds “chromenes”, with high efficiency, for
breast cancer therapy. In this study, we have screened four newly designed and
synthesized chromenes (C1, C15, C28 and C29) for their potential anticancer activities
against the highly aggressive and invasive triple negative breast cancer (TNBC) cells.
We found that three (C1, C15 and C28) of the four tested chromenes exhibited a strong
anti-proliferative activity against the MDA-MB-231 cells. Moreover, we found that
chromenes exerts their anti-breast cancer effect through induction (i) of cell cycle
arrest at the M phase confirmed by an increased expression of the M phase specific
marker, p(ser10)H3 and (ii) activation of the apoptotic cell death program, revealed by
increased levels of cleaved PARP , a marker of apoptosis. Further investigations are
underway to elucidate the molecular mechanism(s) through which chrome exerts their
effects. In conclusion, our current study provide preliminary evidences that chromenes
could be a potential therapeutic compounds against the TNBC.
Keywords: Cancer, Chromenes, anti-cancer agent, apoptosis, cell viability, and cell
cycle.
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)Title and Abstract (in Arabic
فرز مواد كيميائيه مصنعه من ( كرومين) ذات فعاليه مضاده للسرطان

الملخص
السرطان هو السبب الرئيسي ويصنف في المستوي الثاني لسبب الوفيات في العالم .العالجات التقليدية
تتسبب في أثار جانبيه خطيره ,وفي احسن الظروف فهي تعمل علي مجرد اطاله عمر المريض الي بضع سنوات.
ولمكافحه السرطان علينا االستفادة من االمكانات التي تتواجد في العالجات البديلة .وعليه هناك طلبا متزايدا علي
استخدام العالجات البديلة و المسالمة في الوقاية من السرطان .الهدف الرئيسي من هذه الدراسة هو فحص وتحديد
المركبات الصناعية الجديدة " "chromenesبكفاءة عالية و منخفضه السمية لعالج السرطان .
لعالج سرطان الثدي في هذه الدراسة ,قمنا بترتيب أربعة مركبات ل" "chromenesوتوليفها (،C1
 C28 ،C15و )C29و التي صممت حديثا لألنشطة المضادة للسرطان المحتملة و خصيصا ضد سرطان الثدي
السلبي ( )TNBCالذي يعرف بالخاليا الثالثية الشديدة العدوانية والغازية.
في دراستنا وجدنا ان ثالث مركبات من بين األربعة المختارة ل" "chromenesذات مفعول قوي ومؤثر ضد
خاليا سرطان الثدي .وعالوة على ذلك ،وجدنا أن تأثير " "chromenesيقوم على محاربة مرض سرطان
الثدي من خالل (أ)اعتقال ووقف دورة الخلية في المرحلة  Mوهذا ما اكده زيادة عالمه معينه للمرحلة ,M
( P)ser10) H3و (ب) تفعيل برنامج موت الخلية و التي كشفت عنها زيادة مستويات  PARPالمشقوق و الذي
يرمز الى موت الخاليا المبرمج .هنالك المزيد من الدراسات و التحقيقات الجارية لتوضيح اآللية الجزيئية
لمركب " ."chromenesفي الختام ،الدراسة الحالية التي لدينا توفر األدلة األولية ل " "chromenesو الذي
يمكن أن يكون المركب العالجي المحتمل ضد "."TNBC

مفاهيم البحث الرئيسيه :السرطان ,كرومينس ,مواد ضد السرطان ,موت الخاليا المبرمج ,حيويه الخاليا ,دوره
الحياه الخلويه.
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Chapter 1: Introduction
1.0 Literature review
1.1 Cancer
Cancer is defined as an abnormal growth of the cells. These cells acquire defects
in differentiation and in the mechanisms that control cell cycle and/or induce apoptosis
in response to various stresses or DNA damage [1]. Aberrations in gene expression
patterns lie at the heart of tumorigenesis. Such defects increase the ability of cancer
cells to survive, grow, and divide in their original tissue and then to metastasize, which
requires survival and proliferation in other environments [2,3]. The development of
cancer generally requires many steps, each governed by multiple factors, some
dependent on the genetic constitution of the individuals, others dependent on his or her
environment and way of life [4]. Unfortunately, different cancers have different
environmental risk factors, and a population that escapes one such danger is usually
exposed to another.

1.1.1 Incidence of Cancer
Cancer is a major public health problem with 8.2 million deaths from cancer in
the world in 2012. (WHO, 2012). In UAE, 1202 cancer cases were registered in 2007.
Moreover, many studies estimated that the world population will reach 7.5 billion in
2020 and 15 million of which will be diagnosed with cancer, while 12 million people
will die from cancer [4,5]. Cancer incidence and mortality has increased dramatically
in both developed and developing nations. In UAE, cancer is the third leading cause
of death following cardiovascular diseases and accidents.
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1.1.2 Breast Cancer

Breast cancer is the most common threats in women, and the second leading cause
of death following lung cancer [6]. An estimated diagnosed new cases of breast cancer
reach 1.38 million per year with 458000 deaths from breast cancer worldwide [7].
They classified the breast cancer routinely according to stage, pathology, grade and
expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal
growth factor receptor (Her2/neu). Approximately 15% of globally diagnosed breast
cancer are of the highly aggressive and invasive triple-negative (TNBC) which is
defined by the absence of these targets (ER-,PR- and Her2/neu – negative) [8] .

1.1.3 Global Burden of Breast Cancer
Women are at increasingly high risk of breast cancer, due to changing exposures
to reproductive and lifestyle characteristics overtime, making breast cancer a major
health problem worldwide, with incidence rates increasing in most countries in the past
few decades. Breast cancer risk has historically been low in developed countries
compared to what is observed in the developing countries. There are several factors
with this increase and is widely attributed to the ‘‘westernization’’ of lifestyles, an illdefined surrogate for changes in factors such as childbearing, anthropometric
attributes, and lifestyle characteristics. A dramatic reductions in breast cancer
mortality rates in developed countries have been noticed following the introduction of
screening and substantial improvements in treatment [9].
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1.1.4 Causes of Breast Cancer
In general, there are many risk factors cause the breast cancer. For example,
menstrual and reproductive risk factors, radiation factors, lifestyle risk factors which
include body size, physical activity, smoking, alcohol and diet. Genetics, personal, and
family history of breast disease is another factor which play a role in breast cancer [9]
1.1.5 Hallmarks of Cancer
Unlike normal cells, a mutation in the tumor suppressor gene P53, makes cancer
cells more capable of evading the process of programmed cell death "apoptosis". To
maintain nutrient supply, tumor cells induce the formation of new blood vessels
through the process called "angiogenesis". In advance stage of tumorgenesis, the
processes of "migration" and "invasion" happen when cancer cells detach from their
tissues and migrate to invade other tissues and cause damage. According to that, the
"primary tumor" can colonize in another organ and form a "secondary tumor" in a
process termed "metastasis" [10]. Understanding the molecular pathways of cell
division and apoptosis is essential to investigate approaches through which cancer
develops. It is also critical in the process of generation of anticancer treatment.
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Figure 1 Hallmarks of Cancer.

1.2 Cell Cycle
Cell cycle is a process of duplication and division where cells reproduces by
performing an orderly sequence of events in which it duplicates its contents and then
divides in two. Cell cycle has a control system which regulate cell numbers in the
tissues of the body. When the system malfunctions, excessive cell divisions can results
in cancer [11].

1.2.1 The Phases of Cell Cycle
Duplication of DNA in the chromosomes and then segregation of the copies into
two genetically identical daughter cells is the basic function of the cell cycle. Cell cycle
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is controlled by two major phases. In S phase (DNA synthesis), chromosome
duplication occurs and occupies about half of the cell-cycle time in a typical
mammalian cell. After that, chromosome segregation and cell division occur in M
phase (mitosis) and requires much less time. Two major events comprises in M phase,
Nuclear division (mitosis) during which the copied chromosomes are distributed into
a pair of daughter nuclei and cytoplasmic division (cytokinesis), which the cell itself
divides in two [12, 13].
Most cell cycles have extra gap phases to allow more time for growth. G1 phase
between M phase and S phase and G2 phase between S phase and M phase. G1, S, and
G2 together are called "interphase" (figure 2). The two gap phases provide time for the
cell to monitor the internal and external environment to ensure that conditions are
suitable and preparations are complete before the cell commits itself to the major S
and M phases [14].
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Figure 2 Normal cell cycle phases

1.2.2 Cell Cycle Control System
The cell-cycle control system is based on a connected series of biochemical
switches, each of which initiates a specific cell-cycle event. In most eukaryotic cells,
the cell-cycle control system triggers cell-cycle progression at three major regulatory
transitions or checkpoints (figure2). The first checkpoint in late G1 where the cells
enter cell cycle and proceed to S phase. The second is the G2/M checkpoint before the
cell enter to M phase to make sure all DNA replicated and the environment is favorable
for replication. The third is the metaphase-to-anaphase transition, where the control
system stimulates sister-chromatid separation, leading to the completion of mitosis and
cytokinesis. Any problems detected inside or outside the cell, will block the
progression through each of these checkpoint by the control system of cyclins and
cyclin-dependent kinases [10,15,16,17].
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1.2.3 The role of Cyclin-Dependent Protein Kinases (CDKs)
A family of protein kinases known as cyclin-dependent kinases (CDKs) are the
central components of the cell-cycle control system. Any cyclical changes in the
phosphorylation of intracellular proteins that initiate or regulate the major events of
the cell cycle are depend on the activities of these kinases as the cell progresses through
the cycle [15] . The most important proteins that regulate these kinases are cyclins.
Cyclins were originally named because they undergo a cycle of synthesis and
degradation in each cell cycle. The activation of cyclin-CDK complexes that result
from cyclical degradation of cyclins trigger cell-cycle events. Thus, activation of Sphase cyclin-Cdk complexes (S-CDK) initiate S phase, while activation of M-phase
cyclin-Cdk complex (M-CDK) triggers mitosis. The mechanisms that control the
activities of cyclin-Cdk complexes include phosphorylation of the CDK subunit,
binding of CDK inhibitor proteins (CKIs), proteolysis of cyclins, and changes in the
transcription of genes encoding CDK regulators. Two additional enzyme complexes
play a role in the cell-cycle control system, the Anaphase promoting complex (APC/C)
and SCF ubiquitin ligases, which catalyze the ubiquitylation and consequent
destruction of specific regulatory proteins that control critical events in the cycle
[18,19] .
1.2.4 Disrupted CDK Activating Enzyme and CDK Inhibitors
Progression of the cell cycle from one phase to another is allowed by CDKs and
cyclins complexes. The activation of CDKs is controlled by the Cdc25 enzymes
through dephosphorylation, which allow the transition from one phase to another.
There are three members of Cdc25, the Cdc25A, Cdc25B and Cdc25C. the Cdc25A is
mandatory for G1/S transition, while the Cdc25B is required for S phase and Cdc25C
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mediate transition to M phase through the activation of CDK1-cyclin B. Therefore,
mutation in the expression of such proteins lead to dysregulation in the cell cycle
progression and can promote tumergenesis [20].
The other regulatory mechanism for CDK activity involves CDK inhibitor
proteins (CKIs). CKIs are capable of exerting inhibition on cyclin-CDK complexes.
There are two major families of CKI proteins, the Inhibitor Kinase 4 (INK4) family
and the CDK interacting protein/Kinase inhibitory protein (CIP/KIP) family. The
INK4 inhibitors consists of p15(INK4b), p16(INK4a), p18(INK4c) and p19(INK4d),
while the CIP/KIP family consist of CIP1 (p21), KIP1 (p27), and KIP2 (p57),which
can associate with CDK enzymes and prevent cyclin binding [15] . The activation of
these inhibitory proteins is controlled by either internal or external inducers. For
instance, p21 is a downstream target for the tumor suppressor transcription factor
protein p53. Whereas, the activation of p15 and p27 is controlled by the Transforming
Growth Factor Beta (TGF-B) proteins of the surrounding cellular environment [21].
Mutation in these inhibitors can lead to cancer. For example, mutations in CKIs such
as INK4 and p21 are capable of promoting tumorgenesis and found mutated in
aggressive types of cancer such as breast and lung cancers [18].

1.3 Apoptosis
Cells that are irreversibly damaged, no longer needed, or are a threat to the
organism can be eliminated quickly and neatly by a process called programmed cell
death or apoptosis [11].
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Apoptosis depends on proteolytic enzymes called caspases, which cleave specific
intracellular proteins to help kill the cell. One of these intracellular proteins is Poly
(ADP-Ribose) Polymerase (PARP) which help in DNA repair and cell proliferation
and serves as an apoptosis marker once it is cleaved into two large and small subunits
by a caspases. Caspases present as inactive precursors called procaspases. Once
activated, they cleave and activate downstream executioner procaspases, which
activate other executioner procaspases, producing an amplifying, irreversible
proteolytic cascade [10, 22].
There are two distinct pathways that control the activity of procaspases and
leading to apoptosis. The extrinsic pathway is activated by extracellular ligands that
bind to cell-surface death receptor. The death receptors recruit procaspases-8 and 10
via adaptor proteins to form the Death-inducing signaling complex (DISC). The
intrinsic pathway is activated by intracellular signals generated when cells are stressed.
In this pathway, cytochrome C that is released from the intermembrane space of
mitochondria activates Apoptosis protease activating factor 1 (Apaf1). The Apaf1
proteins assemble into apoptosome and recruit and activate procaspase-9. Both antiapoptotic and pro-apoptotic Bcl2 proteins regulate the intrinsic pathway by controlling
the release of mitochondrial intermembrane proteins, while Inhibitor of apoptosis
proteins (IAPs) inhibit activated caspases and promote their degradation [23,24,25].
The ability of cancer cells to evade programmed cell death leads to
carcinogenesis[10] . This is achieved mainly through three stages of dysfunctionality
in the pathway of apoptosis, which involve loss of balance between pro-apoptotic and
anti-apoptotic proteins, impairment in cell death receptors and decreased caspase
activity[26].
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Disruption in apoptosis pathway is also linked to mutation in P53. For instance,
down regulation of mutant P53 has been reported to have a major effect on reducing
the formation of colonies in cancer cells and enhancing apoptosis [27].
The morphological changes in an apoptotic cells summarized in any alterations in
nucleus, cell membrane and in cellular organelles. Moreover, apoptotic cells acquire a
structure of rounded cells [28].

1.4 Treatment
Cancer is treated with radiation, surgery, and chemotherapy. However, these
currently used clinical therapies showed limitations and high morbidity and mortality
rates. Therefore, there is an urgent need for the development of new therapeutic drugs
that will be more efficient, with less side effects or to be used in combination of
existing ones.
The ultimate goal of all anticancer treatments is to selectively eradicate tumor cells,
and the favored mechanism for this is apoptosis . A drawback of this strategy is that
tumor cells frequently develop drug-resistant phenotypes by accumulating alterations
in key regulators of the apoptotic pathway. The drug-resistant phenotype is often
responsible for tumor regrowth and treatment failure [29].
Since microtubules play a critical role in mitosis by creating the mitotic spindle,
tubulin has long been a natural target for chemotherapeutics. The major classes of
microtubule-interacting agents are Taxanes and vinca and Colchicine site binders.
Over expression of β-tubulin isotypes results in decreasing drug accumulation within
the cancer cell due to the ability of pumping out anticancer drugs [30]. Identification
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of new anti-cancer drugs that trigger cell death by acting on alternative pathways, or
on different levels of a given pathway, can overcome resistance to chemotherapy.
Furthermore, the availability of a broad range of anticancer drugs allows choosing
between individual treatments to reduce toxicity [31,32]. Recent developments of
molecular cancer therapeutics have produced new drugs that show promising
antitumor effects in vivo [31].

1.4.1 Chromenes
Chromenes are a polycyclic organic compound that results from the fusion of a
benzene ring to a heterocyclic pyran ring. These compounds play a role as a potential
anticancer agent that can activate or promote apoptosis in cancer cell. Cai,S.X et al
studied the effect of chromenes in T47D cells and they proved that 4H-Chromenes
were identified as potent apoptosis inducers through inducing nuclear fragmentation
and arrest cells at the G2/M stage followed by apoptosis in multiple human cell lines.
4H-Chromenes are developed as chemotherapeutic agents that target the colchicine
binding site and serve as inhibitor for tubulin polymerization and cytotoxic against
human cancer cells. For that, chromenes compound could be further developed as a
potential therapeutic agent for a variety of aggressive cancers [33,34, 35] .
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1.5 Objectives
The objectives of this study are to screen for new synthetic chromenes for their
antiproliferative and proapoptotic effect on triple negative MDA-MB-231 breast
cancer cell line and to study the mechanism(s) of action of these compounds on cancer
cells.
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Chapter 2: Materials and Methods
2.1 Cell Culture
Human cancer cell line of breast origin MDA-MB-231 was maintained in
appropriate cell culture medium DMEM (Hyclone, Cramlington, UK) completed with
10% fetal bovine serum and 2% antibiotic (FBS) (Hyclone, Cramlington, UK). Cells
was maintained in a humidified incubator at 37oC in a 5% CO2 atmosphere.
2.2 Chemical Compounds
Chromene compounds were synthesized by Dr Soleiman Hisaindee from the
department of Chemistry, UAE University. These chemical compounds were
suspended in DMSO at a concentration of 200 µM and stored at -80 oC .

C1

C15

NH 2

C28

C29
NH 2

NH 2

HO

CN

CN

CN

O

O

O
N

N

OH
CN
O

N

Cl

Figure 3 Chromenes compounds’ structures
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2.3 Cell Viability
Cancer cells were seeded in triplicate in 96-well plates at a density of 5,000 cells
/ well. After 24 h, cells were treated with or without various concentrations of
Chromene compounds for different durations. Control cells were treated with vehicle
(DMSO). The effect of drugs on cell viability was determined using Cell Cytotoxicity
Kit (Abcam) according to the manufacturer’s specifications. The data was presented
as proportional viability (%) by comparing the treated group with the untreated cells,
the viability of which is assumed to be 100%.
2.4 Analysis of Morphology
MDA-MB-231 cells treated with C15 with different concentrations were
examined for morphological changes using EVOS Biotechnology inverted microscope
which is equipped with an indigenous camera and pictures were taken with 40X and
400X magnification.
2.5 Western Blot
Cells were seeded with 1.5 million of cells in 100mm dishes and cultured for 24h
with or without the addition of C15. Cells were then washed twice with ice-cold PBS,
scraped and lysed in RIPA buffer. The lysates were centrifuged at 13000 rpm for 30
min at 4ºC after incubation for 30 min in ice. Protein concentration of lysate was
determined by using BCA kit. The total cell lysate were separated via SDS-PAGE and
transferred onto a nitrocellulose membrane. Then, blocked for 1 h at room temperature
with 5% non-fat dried milk in PBST (phosphate buffer saline with 0.05% Tween 20).
Overnight incubation with specific primary antibodies was performed in at 4ºC.
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Horseradish peroxidase-conjugated anti-IgG was used as secondary antibody. The
membranes were then exposed to X-ray film.
2.6 Flow Cytomertic Analysis of Cell Cycle Distribution
Cancer cells were seeded with 300,000 cells in 60mm culture dishes and cultured
for 24 h before addition of various concentrations of C15 compound or equal volume
of vehicle (DMSO) as control. After incubation for the indicated time, cells were
harvested by trypsin release, washed twice with ice-cold PBS, resuspended in PBS,
fixed with an equal volume of 100% ethanol and incubated for at least 12h at -220C.
Before flow cytometry analysis, cells were pelleted, washed twice with PBS. Then
Stained with cell cycle kit (Millipore) and analyzed with MUSE cell analyzer.
Percentage of cells in G1, S and G2/M phases was determined using the FlowJo
software.
2.7 Statistical Analysis
The statistical analysis were done using SPSS version 21. Data were reported as
group mean ± SEM. A student's t-test for paired or unpaired values was performed.
Significance for all statistical comparisons was set at p value of <0.05 using a twotailed test.
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Chapter 3: Results
3.1 Effect of the Chromenes on the Cellular Viability of the MDA-MB-231 Breast
Cancer Cell Line.
To examine the anticancer effect of chromenes on breast cancer cell line, we first
measured the effect of various concentration of chromenes (C1, C15, C28 and C29)
on the proliferation of MDA-MB-231 cell line. Our results showed a nice decrease in
the cellular viability of MDA-MB-231 cell line when exposed to various concentration
of Chromenes (C1, C15 and C28) but not with C29. Furthermore, treatment with 2.5
µM of chromenes 1, 15 and 28 for 24 (Figure 4A) and 48 Hrs (Figure 4B) resulted in
approximately 50% decrease in the cell viability of MDA-MB-231 cell line. The
exposure of MDA-MB-231 to chromenes decreased cellular viability in a
concentration and time-dependent manner compared to a control cells treated with
vehicle (ethanol).
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Figure 4 Inhibition of cellular viability of MDA-MB-231 cells by
Chromenes in concentration and time dependent manner. MDA-MB-231
cells were treated with and without the indicated concentration of
chromenes (1, 15, 28, and 29) for 24hrs (A) and 48hrs (B). viability
monitored as described in materials and methods. Data represent the
mean of four independent experiments carried out in triplicate.
Statistical analysis for cell viability data was performed and reported as
a group of ±SEM. p value of <0.05 was considered statistically
significant.
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3.2 Morphological Changes Induced by Chromene 15 in MDA-MB-231 Cell Line.
Next, we focused our attention to C15 only. To understand the mechanism(s) of
action of this compound (C15) in inhibiting the cellular viability, we first looked at
the morphology of MDA-MB-231 in control and C15-treated cells for 24 hours. As it
is shown in figure 5, light microscopy observation revealed that the number of MDAMB-231 cells in the presence of C15 significantly decreased compared to the control.
Morphological observation also revealed that treated cells exhibited a rounded-shaped
and smaller size a characteristic of apoptotic cells (Figure 5).

X

2.5 µM

x400

x40

Control

Figure 5 Morphological changes in MDA-MB-231 cells treated with C15 for 24
hrs. Images taken at 40x and 400x magnifications. Cells were examined under
EVOS XL Core Cell Imaging System (Life Technologies).
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3.3 Significant Induction Of Apoptosis By C15 In Mda-Mb-231 Cells.
Further investigation of the mechanism of cell death induced by C15 on MDAMB-231 cells, we studied the expression of cleaved PARP in treated cells with
different concentrations of C15 for 24hrs. As shown in figure 6, a high accumulation
of cleaved PARP which is considered as an apoptosis marker was observed, and thus
suggesting the occurrence of apoptosis in C15-treated MDA-MB-231 cells.

Figure 6 Induction of apoptosis by C15 in MDA-MB-231 cells. Cells were treated for
24 hrs with different concentrations of the C15. Western blot analysis was carried out
using anti-cleaved PARP antibody.

3.4 C15 Leads To Mitotic Arrest on Mda-Mb-231 Cell Line
The ability of an anticancer drug to affect cell cycle distribution can provide
information regarding its cytotoxic mechanism(s) of action. Therefore, we investigated
the effect of C15 on cell cycle distribution. To achieve this, cells were treated with
increasing concentrations of C15 for 24 hrs and then cell cycle phases were measured.
At the concentration of 2.5 µM, C15 caused an obvious G2/M arrest as it is shown in
figure 7. Indeed the population of G2/M increased significantly, from 30 to over 60%,
as the concentration of C15 increased indicating that C15-treated MDA-MB-231 cells
underwent cell cycle arrest at G2/M phase.
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G1

G2/

G2/M

Figure 7 Induction of G2/M cell cycle arrest by C15 in MDA-MB-231 cell line. Cells
were exposed to various concentrations of C15 for 24h. After treatment cell analyzed
for cell cycle distribution using flow cytometry. Data are reprentative of three
independent experiments. Percentage of cells in G1, S and G2/M phases was
determined using the FlowJo software. p value of <0.05 was considered statistically
significant.
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3.5 C15 Leads To Upregulation Of P21 Expression In Mda-Mb-231 Cells
It is well known that the cyclin dependent kinase (CDK) inhibitor p21 cause a
cell cycle arrest when cells are exposed to anticancer compounds [15]. Because we
found that C15 induces cell cycle arrest at G2/M phase in C15-treated cells, we decided
to examine the level of p21, by Western Blot, in response to C15. As shown in figure
8, the expression of p21 increased in MDA-MB-231 cell treated with low
concentrations (1 and 5 µM) of C15. Interestingly a higher concentration of C15 (10
µM) did not show a change in p21 level. Still we cannot rule out the possibility that
p21 increased at early time point but due to massive cell death at high concentration,
the protein undergoes degradation. From this result we can conclude that C15 induce
cell cycle arrest through induction of the CDK inhibitor, p21.

Figure 8 Expression of p21 in C15-treated MDA-MB-231 cells. Cells were treated
with various concentrations of C15 or vehicle as a control for 24 h and the expression
of p21 was estimated by Western Blot.

3.6 Phosphorylation Status of H3 (Ser 10) Detected In C15-Treated Mda-Mb-231
Cells
To determine whether C15 induce cell cycle arrest specifically at mitosis or G2
phase, we analyzed the expression of G2 and M phase specific markers, cyclin B and
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histone H3-phospho (Ser 10), respectively by Western Blot. Figure 9 showed that the
level of C15- treated cells significantly increase the phosphorylation level of H3phospho (Ser 10) in dose-dependent manner in response to C15. The level of cyclin
B1 on the other hand remained unaffected (Figure 9). Altogether, our results indicates
that C15 induces a specific cell cycle arrest at the M phase.

Figure 9 Expression of cell cycle regulator in C15-treated MDA-MB-231.Western
blot analysis of phosphor (ser10)-H3 and cyclin B1 in MDA-MB-231 cells exposed
for 24 h with ethanol or indicated concentrations of C15.

3.7 Effect Of C15 In The Dna Damage Of Mda-Mb-231 Cells
Finally, we tested whether C15 mediates its effect through induction of DNA
damage as it is the case for numerous ancticancer compounds. Toward this, we
examined the level of the marker of DNA damage ɣ-H2AX in treated-cells by Western
Blot. As it is shown in figure 10, C15 did not induce any significant increase on the
level of ɣ-H2AX, thus indicated that C15 mediated effect is independent of DNA
damage.
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Figure 10 Effect of C15 in the DNA damage of MDA-MB-231 cells. C15 did not cause
a DNA damage in MDA-MB-231 cells. western blot analysis of phospo-H2AX in
MDA-MB-231 cells exposed for 24 h with indicated concentrations of C15 or vehicle
as a control.
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Chapter 4: Discussion
The main goal of anticancer drugs is to inhibit cell cycle progression and induce
cell death. Many natural products play a role in these two events and act as anticancer
drugs in the field of cancer treatment. Hence, we started our investigation for potential
anticancer effect of C15 by testing its cytotoxicity effect and its ability to induce cell
death in MDA-MB-231 cell line.
In our study, we have shown that chromenes play a role in inhibiting cellular
viability and inducing apoptosis. This result was clear in the cytotoxicity assay and in
the morphology of the MDA-MB-231 cells treated with different concentrations of
chromenes. Apoptosis was further confirmed by PARP cleavage expression which was
detected by Western blot.
Furthermore, cell cycle represents another target in developing chemotherapy
against cancer cells [36]. Interestingly, our results showed that C15 induced cell cycle
arrest at G2/M phase and more precisely at the M phase. This result was further
supported by Western blotting analysis of specific marker to mitotic arrest which
revealed an increased level of H3-phospho (Ser10). Interestingly, we found that cell
cycle arrest correlated with an upregulation of the CDK inhibitor p21. Indeed, p21 is
known to block cell cycle by binding to CDK and thus inhibiting its activity. Several
studies suggested a pro-apoptotic role for p21. Indeed, it was revealed that apoptosis
coexisted with induction of p21 without defining whether p21 is needed for the
induction of apoptosis [37]. Hence, we cannot rule out a potential involvement of p21
in the induction of apoptosis in response to chromenes.
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Since microtubules play a critical role in mitosis by creating the mitotic spindle,
tubulin has long been a natural target for chemotherapeutics [38]. The most commonly
prescribed successful anticancer therapies, that target microtubules are Paclitaxel and
Docetaxel. These two chemotherapy agents play a role in Taxane binding site which
serve as one of the major classes of microtubule-interacting agents [39,40] . The other
two classes are Vinca and Colchicine site binders. Vincristine and Vinblastine are
clinically applied microtubule-interacting agents that bind with Vinca alkaloid site [41]
. The widespread clinical use of these agents in a variety of cancers reveal the
importance of tubulin and its role in cancer. Interestingly, in our study, we showed
that chromenes induces targeted breast cancer cells through induction of mitotic block
with subsequent activation of the apoptotic pathway. We also showed that mitotic
block is not a consequence of genotoxic effect of the chromenes as no significant DNA
damage was detected in treated-cells. Hence we can speculate that chromenes might
induce mitotic block through targeting the assembly of the mitotic spindle or inducing
microtubule depolymerization, possibly by targeting the tubulin. Further investigation
to examine this hypothesis is underway in the lab.
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Chapter 5: Conclusion

In conclusion, in this study we showed that the newly designed chromenes affect
significantly inhibited cellular viability of TNBC in a concentration- and timedependent manner. Moreover, chromenes induced cell cycle arrest and apoptosis and
upregulated the CDK inhibitor p21. Results from this study provide preliminary
evidence that chromenes possesses a potential anti-cancer activity against the most
aggressive and invasive form of breast cancer and therefore deserves more attention
for further investigations to study the mechanism(s) of action of these compounds.
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